Human embryo genes modified with unprecedented precision for the first time

In a significant scientific first, researchers have precisely modified genes in early-stage human embryos to correct defects that cause diseases. This breakthrough was achieved using a novel technique that alters single DNA bases, the fundamental building blocks of genetic code, akin to a molecular proofreader.

The experiment, conducted at Columbia University in New York, serves as a proof of principle to demonstrate the technique's efficiency. The new method, named Adenine Base Editor (ABE), is an advancement of CRISPR technology. Unlike CRISPR's "molecular scissors" that cut DNA, ABE acts more like a "pencil," modifying individual DNA letters without breaking the strands. A crucial aspect is that it does not induce segmental aneuploidies, which are a major cause of embryonic developmental failure.

Giuseppe Novelli, a geneticist at the University of Rome Tor Vergata, praised the study's methodological rigor. He noted that the ability to avoid genetic alterations in DNA segments and the programming of embryo development arrest are clinically relevant findings. However, Novelli also raised concerns, particularly regarding the involvement of authors from Genomic Prediction, a company specializing in prenatal genetic testing. While not invalidating the data, he stressed the need for transparency.

Several critical challenges remain before any potential clinical applications. These include the issue of mosaicism, where corrected and uncorrected cells coexist, and the small sample size, which limits statistically reliable conclusions. Ethical considerations are also paramount, as the leap from technical demonstration to clinical application necessitates a broad debate beyond the scientific community. Lead researcher Dieter Egli emphasized that the technique requires further refinement and is not ready for immediate clinical use, advocating for public discussion on the advantages and disadvantages of embryonic DNA modification.

“

Come scienziato - ha detto al New York Times - puoi fornire i dati su cui discutere, ma poi, in sostanza, il tuo compito finisce lì e lasci che siano altri a proseguire